Cargando…

Outcomes of Critically Ill Lung Transplant Recipients with COVID-19

PURPOSE: Critically ill patients with COVID-19 are at high risk of morbidity and mortality. This risk may be even higher among lung transplant recipients (LTxRs) as they are immunosuppressed and typically older with multiple co-morbidities. The aim of this study was to characterize the outcomes of c...

Descripción completa

Detalles Bibliográficos
Autores principales: Razia, D., Padiyar, J., Schaheen, L., Grief, K., Walia, R., Tokman, S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8988755/
http://dx.doi.org/10.1016/j.healun.2022.01.1547
_version_ 1784683033265176576
author Razia, D.
Padiyar, J.
Schaheen, L.
Grief, K.
Walia, R.
Tokman, S.
author_facet Razia, D.
Padiyar, J.
Schaheen, L.
Grief, K.
Walia, R.
Tokman, S.
author_sort Razia, D.
collection PubMed
description PURPOSE: Critically ill patients with COVID-19 are at high risk of morbidity and mortality. This risk may be even higher among lung transplant recipients (LTxRs) as they are immunosuppressed and typically older with multiple co-morbidities. The aim of this study was to characterize the outcomes of critically ill LTxRs with COVID-19. METHODS: LTxRs with COVID-19 hospitalized in the ICU between 06/01/2020 and 02/28/2021 were included and classified as alive or deceased. Baseline clinical characteristics, laboratory results, and complications were reviewed. Death due to COVID-19 was the primary outcome. Descriptive statistics were used. RESULTS: Twenty-five LTxRs (13 men; 8 alive, 17 deceased) were included. Median (IQR) age, interval between LTx and COVID-19 diagnosis, and duration of ICU stay was 66 years (56, 71), 27 months (10, 51), and 19 days (10, 28), respectively. Pre-existing diabetes and chronic kidney disease were common (68%, 68%). Although statistical significance was not reached due to small sample size, survivors trended toward lower levels of CRP, ferritin, and D-Dimer at ICU admission. Fewer survivors had a stroke (0% vs 6%), hemorrhage requiring transfusion (14% vs 18%), new-onset heart failure (14% vs 29%), venous thromboemboli (24% vs 33%), and renal failure requiring dialysis (25% vs 53%). At a median of 8 days after COVID-19 diagnosis, 18 (72%) LTxRs required intubation. The need for mechanical ventilation increased the risk of death 4.327-fold (p=0.054) and lowered the probability of 60-day survival (16.7% vs 71.4%, p=0.035; Figure 1). The median survival of deceased subjects was 23 days (17, 34). Most LTxRs received corticosteroids, convalescent plasma, remdesevir, and reduced immunosuppression. Among LTxRs that survived to hospital discharge, 38% (3) were discharged home, 50% (4) required acute rehabilitation, and 75% (6) were supplemental oxygen dependent. CONCLUSION: Critically ill LTxRs with COVID-19 have high morbidity and mortality. The need for mechanical ventilation portends a poor prognosis.
format Online
Article
Text
id pubmed-8988755
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Published by Elsevier Inc.
record_format MEDLINE/PubMed
spelling pubmed-89887552022-04-11 Outcomes of Critically Ill Lung Transplant Recipients with COVID-19 Razia, D. Padiyar, J. Schaheen, L. Grief, K. Walia, R. Tokman, S. J Heart Lung Transplant (968) PURPOSE: Critically ill patients with COVID-19 are at high risk of morbidity and mortality. This risk may be even higher among lung transplant recipients (LTxRs) as they are immunosuppressed and typically older with multiple co-morbidities. The aim of this study was to characterize the outcomes of critically ill LTxRs with COVID-19. METHODS: LTxRs with COVID-19 hospitalized in the ICU between 06/01/2020 and 02/28/2021 were included and classified as alive or deceased. Baseline clinical characteristics, laboratory results, and complications were reviewed. Death due to COVID-19 was the primary outcome. Descriptive statistics were used. RESULTS: Twenty-five LTxRs (13 men; 8 alive, 17 deceased) were included. Median (IQR) age, interval between LTx and COVID-19 diagnosis, and duration of ICU stay was 66 years (56, 71), 27 months (10, 51), and 19 days (10, 28), respectively. Pre-existing diabetes and chronic kidney disease were common (68%, 68%). Although statistical significance was not reached due to small sample size, survivors trended toward lower levels of CRP, ferritin, and D-Dimer at ICU admission. Fewer survivors had a stroke (0% vs 6%), hemorrhage requiring transfusion (14% vs 18%), new-onset heart failure (14% vs 29%), venous thromboemboli (24% vs 33%), and renal failure requiring dialysis (25% vs 53%). At a median of 8 days after COVID-19 diagnosis, 18 (72%) LTxRs required intubation. The need for mechanical ventilation increased the risk of death 4.327-fold (p=0.054) and lowered the probability of 60-day survival (16.7% vs 71.4%, p=0.035; Figure 1). The median survival of deceased subjects was 23 days (17, 34). Most LTxRs received corticosteroids, convalescent plasma, remdesevir, and reduced immunosuppression. Among LTxRs that survived to hospital discharge, 38% (3) were discharged home, 50% (4) required acute rehabilitation, and 75% (6) were supplemental oxygen dependent. CONCLUSION: Critically ill LTxRs with COVID-19 have high morbidity and mortality. The need for mechanical ventilation portends a poor prognosis. Published by Elsevier Inc. 2022-04 2022-04-07 /pmc/articles/PMC8988755/ http://dx.doi.org/10.1016/j.healun.2022.01.1547 Text en Copyright © 2022 Published by Elsevier Inc. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle (968)
Razia, D.
Padiyar, J.
Schaheen, L.
Grief, K.
Walia, R.
Tokman, S.
Outcomes of Critically Ill Lung Transplant Recipients with COVID-19
title Outcomes of Critically Ill Lung Transplant Recipients with COVID-19
title_full Outcomes of Critically Ill Lung Transplant Recipients with COVID-19
title_fullStr Outcomes of Critically Ill Lung Transplant Recipients with COVID-19
title_full_unstemmed Outcomes of Critically Ill Lung Transplant Recipients with COVID-19
title_short Outcomes of Critically Ill Lung Transplant Recipients with COVID-19
title_sort outcomes of critically ill lung transplant recipients with covid-19
topic (968)
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8988755/
http://dx.doi.org/10.1016/j.healun.2022.01.1547
work_keys_str_mv AT raziad outcomesofcriticallyilllungtransplantrecipientswithcovid19
AT padiyarj outcomesofcriticallyilllungtransplantrecipientswithcovid19
AT schaheenl outcomesofcriticallyilllungtransplantrecipientswithcovid19
AT griefk outcomesofcriticallyilllungtransplantrecipientswithcovid19
AT waliar outcomesofcriticallyilllungtransplantrecipientswithcovid19
AT tokmans outcomesofcriticallyilllungtransplantrecipientswithcovid19